The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid
Open accessAbstract
INTRODUCTION: Available assays for quantitation of the Alzheimer's disease (AD) biomarker amyloid-beta 1-42 (Aβ [1-42]) in cerebrospinal fluid demonstrate significant variability and lack of standardization to reference measurement procedures (RMPs). We report analytical performance data for the novel Elecsys β-amyloid (1-42) assay (Roche Diagnostics). METHODS: Lot-to-lot comparability was tested using method comparison. Performance parameters were measured according to Clinical & Laboratory Standards Institute (CLSI) guidelines. The assay was standardized to a Joint Committee for Traceability in Laboratory Medicine (JCTLM) approved RMP. RESULTS: Limit of quantitation was <11.28 pg/mL, and the assay was linear throughout the measuring range (200-1700 pg/mL). Excellent lot-to-lot comparability was observed (correlation coefficients [Pearson's r] >0.995; bias in medical decision area <2%). Repeatability coefficients of variation (CVs) were 1.0%-1.6%, intermediate CVs were 1.9%-4.0%, and intermodule CVs were 1.1%-3.9%. Estimated total reproducibility was 2.0%-5.1%. Correlation with the RMP was good (Pearson's r, 0.93). DISCUSSION: The Elecsys β-amyloid (1-42) assay has high analytical performance that may improve biomarker-based AD diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, fully automated immunoassays have been developed by several different vendors with improved reliability and precision for CSF Aβ and tau species.23,24,25”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Passing, H., & Bablok, W. (1983) · cclm · doi:10.1515/cclm.1983.21.11.709 · Cited by 1,513
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 649
Research works printed but not linked: 8
- Clinical Laboratory and Standards Institute (CLSI), 2012, Evaluation of detection capability for clinical laboratory measurement procedures: Approved guideline—Second edition. CLSI Document EP17–A2
- Clinical Laboratory and Standards Institute (CLSI), 2003, Evaluation of the linearity of quantitative measurement procedures: A statistical approach; approved guideline. CLSI Document EP06‐A
- Clinical Laboratory and Standards Institute (CLSI), 2013, Measurement procedure comparison and bias estimation using patient samples; approved guideline—Third edition. CLSI Document EP09–A3
- Clinical Laboratory and Standards Institute (CLSI), 2005, Interference testing in clinical chemistry; approved guideline—Second edition. CLSI Document EP7–A2
- Clinical Laboratory and Standards Institute (CLSI), 2008, Immunoassay interference by endogenous antibodies; approved guideline. CLSI Document I/LA30‐A
- Clinical Laboratory and Standards Institute (CLSI), 2014, Evaluation of precision of quantitative measurement procedures; approved guideline—Third edition. CLSI Document EP05–A3
- Clinical Laboratory and Standards Institute (CLSI), 2014, User verification of performance for precision and trueness; approved guideline—Second edition. CLSI Document EP15–A2
- Scheltens P, 2014, Baseline patient characteristics from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD, J Prev Alzheimers Dis, 1, 231
Cited by
Sorted by citations
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citationDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808
Self-citationMattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Self-citationA phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.006 · Cited by 523
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease
Lucey, B. P., McCullough, A. A., Landsness, E. C., Toedebusch, C. D., McLeland, J., Zaza, A., Fagan, A. M., McCue, L. M., Xiong, C., Morris, J. C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6550 · Cited by 386
Nho, K., Kueider‐Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.012 · Cited by 343
Initiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 351
Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Huang, S., Zhang, Y.-R., Guo, Y., Du, J., Ren, P., Wu, B., Feng, J., Initiative, A. D. N., Cheng, W., & Yu, J. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13789 · Cited by 305
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.013 · Cited by 284
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C. T., Cho, W., Ward, M. E., Friesenhahn, M. J., Rabe, C., Brunstein, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005550 · Cited by 261
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., Schöll, M., et al. (2021) · Brain · doi:10.1093/brain/awaa399 · Cited by 229
Nho, K., Kueider-Paisley, A., Ahmad, S., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.7978 · Cited by 227
Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
Arnold, M., Nho, K., Kueider-Paisley, A., Massaro, T., Huynh, K., Brauner, B., MahmoudianDehkordi, S., Louie, G., Moseley, M. A., Thompson, J. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14959-w · Cited by 202
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183
Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
for the Alzheimer’s Disease Neuroimaging Initiative, F. T. A. S., Salvadó, G., Molinuevo, J. L., Brugulat-Serrat, A., Falcon, C., Grau-Rivera, O., Suárez-Calvet, M., Pavia, J., Niñerola-Baizán, A., Perissinotti, A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0478-z · Cited by 195
Self-citationBlennow, K., Shaw, L. M. J., Stomrud, E., Mattsson, N., Toledo, J. B., Buck, K., Wahl, S., Eichenlaub, U., Lifke, V., Simon, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54204-z · Cited by 194
Leitão, M. J., Silva‐Spínola, A., Santana, I. J., Olmedo, V., Nadal, A., Bastard, N. L., & Baldeiras, I. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0550-8 · Cited by 164
Salloway, S., Honigberg, L. A., Cho, W., Ward, M. E., Friesenhahn, M. J., Brunstein, F., Quartino, A. L., Clayton, D., Mortensen, D. L., Bittner, T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0424-5 · Cited by 156
Caminiti, S. P., Ballarini, T., Sala, A., Cerami, C., Presotto, L., Santangelo, R., Fallanca, F., Vanoli, E. G., Gianolli, L., Iannaccone, S., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.019 · Cited by 153
The Past and the Future of Alzheimer’s Disease Fluid Biomarkers
Blennow, K., & Zetterberg, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170773 · Cited by 154
Janelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147
Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
Bucci, M., Chiotis, K., Nordberg, A., & Initiative, F. T. A. D. N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01263-2 · Cited by 140
Hulle, C. V., Jonaitis, E. M., Betthauser, T. J., Batrla, R., Wild, N., Kollmorgen, G., Andréasson, U., Okonkwo, O. C., Bendlin, B. B., Asthana, S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12204 · Cited by 132
Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136
CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation
Kuhlmann, J., Andréasson, U., Pannee, J., Bjerke, M., Portelius, E., Leinenbach, A., Bittner, T., Korecka, M., Jenkins, R. G., Vanderstichele, H., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.014 · Cited by 139
Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123
Meyer, P., Binette, A. P., Gonneaud, J., Breitner, J. C. S., Villeneuve, S., & ADNI Investigators (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4749 · Cited by 126
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
Irwin, D. J., Fedler, J. K., Coffey, C. S., Caspell‐Garcia, C., Kang, J., Simuni, T., Foroud, T., Toga, A. W., Tanner, C. M., Kieburtz, K. D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25811 · Cited by 108
Willemse, E. A. J., van Maurik, I. S., Tijms, B. M., Bouwman, F. H., Franke, A., Hubeek, I., Boelaarts, L., Claus, J. J., Korf, E. S. C., van Marum, R. J., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.08.006 · Cited by 110
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99
Self-citationBoccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O. O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 94
From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease
Zetterberg, H., & Blennow, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179926 · Cited by 98
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Thomas, K. R., Edmonds, E. C., Eppig, J. S., Salmon, D. P., Bondi, M. W., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180229 · Cited by 96
Lifke, V., Kollmorgen, G., Manuilova, E., Oelschlaegel, T., Hillringhaus, L., Widmann, M., Arnim, C. A. F. V., Otto, M., Christenson, R. H., Powers, J. L., et al. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.05.005 · Cited by 94
Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
van Harten, A. C., Wiste, H. J., Weigand, S. D., Mielke, M. M., Kremers, W. K., Eichenlaub, U., Dyer, R. B., Algeciras‐Schimnich, A., Knopman, D. S., Jack, C. R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12406 · Cited by 91
Yang, T., Dang, Y., Ostaszewski, B., Mengel, D., Steffen, V., Rabe, C., Bittner, T., Walsh, D. M., & Selkoe, D. J. (2019) · Annals of Neurology · doi:10.1002/ana.25513 · Cited by 91
Buckley, R. F., Mormino, E. C., Chhatwal, J. P., Schultz, A. P., Rabin, J. S., Rentz, D. M., Acar, D., Properzi, M. J., Dumurgier, J., Jacobs, H. I. L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.019 · Cited by 89
Statistical Disease Progression Modeling in Alzheimer Disease
Rakêt, L. L., & Initiative, F. T. A. D. N. (2020) · Frontiers in Big Data · doi:10.3389/fdata.2020.00024 · Cited by 78
Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Shaw, L. M. J., Waligórska, T., Fields, L., Korecka, M., Figurski, M., Trojanowski, J. Q., Eichenlaub, U., Wahl, S., Quan, M., Pontecorvo, M. J., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.002 · Cited by 81
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey‐Smith, S. R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00595-5 · Cited by 81
Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease
McIntosh, E. C., Nation, D. A., & Initiative, A. D. N. (2019) · Diabetes Care · doi:10.2337/dc18-1399 · Cited by 82
P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
Campbell, M. R., Ashrafzadeh‐Kian, S., Petersen, R. C., Mielke, M. M., Syrjanen, J. A., van Harten, A. C., Lowe, V. J., Jack, C. R., Bornhorst, J. A., & Algeciras‐Schimnich, A. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12190 · Cited by 79
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 78
Franzmeier, N., Koutsouleris, N., Benzinger, T. L. S., Goate, A., Karch, C. M. M., Fagan, A. M., McDade, E., Duering, M., Dichgans, M., Levin, J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12032 · Cited by 76
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Mattsson, N., Palmqvist, S., Blennow, K., & Hansson, O. (2020) · Nature Communications · doi:10.1038/s41467-020-19957-6 · Cited by 70
Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
Chen, S.-D., Lu, J.-Y., Li, H.-Q., Yang, Y.-X., Jiang, J.-H., Cui, M., Zuo, C.-T., Tan, L., Dong, Q., Yu, J.-T., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01602-5 · Cited by 71
Shen, X., Huang, Y., Chen, S.-D., Guo, Y., Tan, L., Dong, Q., Yu, J., Initiative, A. D. N., Weiner, M. W., Aisen, P., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01709-9 · Cited by 74
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
de Wilde, A., van Maurik, I. S., Kunneman, M., Bouwman, F. H., Zwan, M. D., Willemse, E. A. J., Biessels, G. J., Minkman, M. M. N., Pel‐Littel, R. E., Schoonenboom, N. S. M., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.003 · Cited by 70
Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Amft, M., Ortner, M., Eichenlaub, U., Goldhardt, O., Diehl‐Schmid, J., Hedderich, D. M., Yakushev, I. Y., & Grimmer, T. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01003-w · Cited by 69
Guo, Y. X., Chen, S.-D., You, J., Huang, S.-Y., Chen, Y., Zhang, Y., Wang, L., He, X., Deng, Y., Zhang, Y.-R., et al. (2024) · Nature Human Behaviour · doi:10.1038/s41562-024-01924-6 · Cited by 71
Wang, Y., Chen, J., Du, Z., Weng, H., Zhang, Y., Li, R., Jia, Z., Sun, M., Jiang, J., Wang, F.-Z., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.695696 · Cited by 64
First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
Boulo, S., Kuhlmann, J., Andréasson, U., Brix, B., Venkataraman, I., Herbst, V., Rutz, S., Manuilova, E., Vandijck, M. L. J., Dekeyser, F., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12145 · Cited by 65
Modeste, E. S., Ping, L., Watson, C. M., Duong, D. M., Dammer, E. B., Johnson, E. C. B., Roberts, B. R., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00638-z · Cited by 66
Spatial navigation ability predicts progression of dementia symptomatology
Levine, T. F., Allison, S. L., Stojanovic, M., Fagan, A. M., Morris, J. C., & Head, D. M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12031 · Cited by 62
Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 67
Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
Chen, S.-D., Huang, Y., Shen, X., Guo, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01476-7 · Cited by 64
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 72
Willemse, E. A. J., Tijms, B. M., van Berckel, B. N. M., Bastard, N. L., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12182 · Cited by 62
Cumplido‐Mayoral, I., García-Prat, M., Operto, G., Falcón, C., Shekari, M., Cacciaglia, R., Milà‐Alomà, M., Lorenzini, L., Ingala, S., Wink, A. M., et al. (2023) · eLife · doi:10.7554/elife.81067 · Cited by 74
Bharadwaj, P., Solomon, T., Malajczuk, C. J., Mancera, R. L., Howard, M. J., Arrigan, D. W. M., Newsholme, P., & Martins, R. N. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.015 · Cited by 63
Sequence of Alzheimer disease biomarker changes in cognitively normal adults
Luo, J. R., Agboola, F., Grant, E., Masters, C. L., Albert, M., Johnson, S. C., McDade, E., Vöglein, J., Fagan, A. M., Benzinger, T. L. S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010747 · Cited by 59
Watson, C. M., Dammer, E. B., Ping, L., Duong, D. M., Modeste, E. S., Carter, E. K., Johnson, E. C. B., Levey, A. I., Lah, J. J., Roberts, B. R., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02158-3 · Cited by 59
A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
Aksman, L., Oxtoby, N. P., Scelsi, M. A., Wijeratne, P. A., Young, A. L., Alves, I. L., Collij, L. E., Vogel, J. W., Barkhof, F., Alexander, D. C., et al. (2023) · Brain · doi:10.1093/brain/awad232 · Cited by 69
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Mielke, M. M., Aakre, J. A., Algeciras‐Schimnich, A., Proctor, N. K., Machulda, M. M., Eichenlaub, U., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Jack, C. R., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12415 · Cited by 55
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Delaby, C., Teunissen, C. E., Blennow, K., Alcolea, D. A., Arisi, I., Bouaziz-Amar, É., Beaume, A., Bedel, A., Bellomo, G., Bigot‐Corbel, E., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12545 · Cited by 57
Blennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 61
Mollenhauer, B., Bowman, F. D., Drake, D. F., Duong, J., Blennow, K., El‐Agnaf, O. M. A., Shaw, L. M. J., Masucci, J., Taylor, P., Umek, R. M., et al. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14569 · Cited by 55
Towards a unified protocol for handling of CSF before β-amyloid measurements
Janelidze, S., Stomrud, E., Brix, B., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0517-9 · Cited by 54
Park, Y. H., Hodges, A., Risacher, S. L., Lin, K., Jang, J., Ahn, S., Kim, S., Lovestone, S., Simmons, A., Weiner, M. W., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.001 · Cited by 53
Karki, H. P., Jang, Y., Jung, J., & Oh, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00814-7 · Cited by 51
Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51
Moscoso, A., Karikari, T. K., Grothe, M. J., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., & Schöll, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12570 · Cited by 50
Gender Differences in Elderly With Subjective Cognitive Decline
Wang, L., Tian, T., & Initiative, A. D. N. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00166 · Cited by 50
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years
Schindler, S. E., Sutphen, C. L., Teunissen, C. E., McCue, L. M., Morris, J. C., Holtzman, D. M., Mulder, S. D., Scheltens, P., Xiong, C., & Fagan, A. M. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.2264 · Cited by 48
Fiorenzato, E., Biundo, R., Cecchin, D., Frigo, A. C., Kim, J., Weis, L., Strafella, A. P., & Antonini, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180390 · Cited by 48
Yoshida, K. J., Moein, A., Bittner, T., Ostrowitzki, S., Lin, H. H., Honigberg, L. A., Jin, J. Y., & Quartino, A. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0580-2 · Cited by 48
Kang, M. S., Aliaga, A., Shin, M., Mathotaarachchi, S. S., Benedet, A. L., Pascoal, T. A., Therriault, J., Chamoun, M., Savard, M., Devenyi, G. A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0818-1 · Cited by 47
Du, L., Langhough, R. E., Wilson, R. E., Reyes, R. E. R., Hermann, B. P., Jonaitis, E. M., Betthauser, T. J., Chin, N. A., Christian, B., Chaby, L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14100 · Cited by 46
Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D. A., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678011 · Cited by 49
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 54
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46
Dakterzada, F., Ortega, R. L., Arias, A. M., Llena, I. R., Ruiz-Julián, M., Huerto, R. P., Tahan, N., & Piñol‐Ripoll, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.604119 · Cited by 47
Salvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46
Self-citationJang, H., Park, J., Woo, S., Kim, S., Kim, H. J., Na, D. L., Lockhart, S. N., Kim, Y., Kim, K. W., Cho, S. H., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101941 · Cited by 46
Neuropsychological Profiles and Trajectories in Preclinical Alzheimer’s Disease
Ho, J. K., Nation, D. A., & Initiative, A. D. N. (2018) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771800022x · Cited by 52
Metadata
- Authors
- Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., Heiss, P., Kobold, U., Leinenbach, A., Madin, K., Manuilova, E., Rabe, C., & Blennow, K.
- Affiliations
- Roche Diagnostics GmbH Penzberg Germany
- UCL Queen Square Institute of Neurology (GB)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Washington University in St. Louis (US)
- Covance (United States) (US)
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology The Sahlgrenska Academy at University of Gothenburg Mölndal Sweden
- University of Gothenburg (SE)
- Corresponding author
- Blennow, Kaj
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-11-07
- Volume
- 12
- Issue
- 5
- Pages
- 517-526
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2111951761
- Cited by
- 374
- References
- 37
- Citations by year
- 2026: 27 · 2025: 41 · 2024: 49 · 2023: 29 · 2022: 35 · 2021: 52 · 2020: 41 · 2019: 39 · 2018: 33 · 2017: 15 · 2016: 11
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Roche Diagnostics GmbH
- Torsten Söderberg Foundation
- Topics
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta 42, cerebrospinal fluid
- MeSH terms
- Alzheimer Disease, Humans, Immunoassay, Peptide Fragments, Reference Standards, Reproducibility of Results, Biomarkers, Amyloid beta-Peptides, Luminescence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
